Issues: Vax Specific

Anthrax

Hepatitis B

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

● 2009 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

FirstPreviousNextLast

Dr. Halsey's presentation at the National Vaccine Advisory Committee Workshop on Thimerosal and Vaccines held in Bethesda, Maryland on August 11-12, 1999.

Slide 11 of 26

Slide Notes:

Exposure to a fixed dose (e.g. 62.5 ug) of mercury at 2 months of age poses a greater potential risk than the same dose administered at 6 months of age because a child weighs more at 6 months and the target organ, the brain, is more vulnerable early in life.

Similarly, exposures at 9-12 months would carry much less theoretical risk than exposure to the same dose at 2 months of age.

The recent American Academy of Pediatrics/ Public Health Service recommendation to defer the first dose of hepatitis B vaccine for infants born to HBsAg negative mothers until 2-6 months of age has addressed the problem of exposure at birth, but the exposure to mercury at 2 months of age is much greater and we need to do more to reduce this potential exposure.